Andrea Forschner

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Lars Hofmann, Andrea Forschner, Carmen Loquai et al. · European Journal of Cancer · 2016 · 638 citations

Urology, Hepatology, Anti-pd-1 Therapy +9

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Lisa Zimmer, Simone M. Goldinger, Lars Hofmann et al. · European Journal of Cancer · 2016 · 552 citations

Translational Medicine, Heart Failure, Cardiovascular Disease +4

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Andrea Forschner, Florian Battke, Dirk Hadaschik et al. · Journal for ImmunoTherapy of Cancer · 2019 · 202 citations · Full text

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler et al. · European Journal of Cancer · 2017 · 196 citations

Prognostic Factors, Programmed Cell Death-1, Medicine +9

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu et al. · European Journal of Cancer · 2017 · 179 citations

Anti-pd-1 Therapy, Medicine, Melanoma +8